Table 3.
Multiple Cox regression analysis of AGR in patients with advanced NSCLC treated with anlotinib
| Exposure | Crude model | Minimally adjusted model | Fully adjusted model |
|---|---|---|---|
| Hazard ratio (95% CIs), p-value | Hazard ratio (95% CIs), p-value | Hazard ratio (95% CIs), p-value | |
| AGR | 0.47 (0.26, 0.84) 0.0105 | 0.53 (0.29, 0.96) 0.0365 | 0.40 (0.18, 0.88) 0.0230 |
| AGR (tertiles) | |||
| Low | Ref | Ref | Ref |
| Middle | 0.58 (0.36, 0.95) 0.0293 | 0.58 (0.35, 0.96) 0.0332 | 0.65 (0.36, 1.16) 0.1410 |
| High | 0.52 (0.32, 0.84) 0.0080 | 0.55 (0.33, 0.91) 0.0187 | 0.49 (0.26, 0.92) 0.0273 |
| p for trend | 0.0073 | 0.0164 | 0.0277 |
Crude model adjusted for: None
Minimally adjusted model adjusted for: Age; Gender; Never smoker
Fully adjusted model adjusted for: Age, years; Gender; Never smoker; Hypertension; ALK rearrangement; EGFR mutation; Histology; Tumor stage; ECOG PS score; Number of metastases; Number of previous treatment lines; Number of previous chemotherapy lines; Previous targeted therapy; Previous radiotherapy; Previous immunotherapy; Anlotinib monotherapy; Leukocyte; Neutrophil; Lymphocyte; Platelets. Restricted cubic spline was applied